Journal
FRONTIERS IN BIOSCIENCE-LANDMARK
Volume 18, Issue -, Pages 1312-1335Publisher
FRONTIERS IN BIOSCIENCE INC
DOI: 10.2741/4181
Keywords
AML; Antibody; Calicheamicin; CD33; Gemtuzumab ozogamicin; Immunoconjugate; Review
Categories
Funding
- National Cancer Institute/National Institutes of Health [P30-CA015704-35S6, R21-CA155524]
- Hope Foundation
- Alex's Lemonade Stand Foundation
Ask authors/readers for more resources
Antibodies have created high expectations for effective yet tolerated therapeutics in acute myeloid leukemia (AML). Hitherto the most exploited target is CD33, a myeloid differentiation antigen found on AML blasts in most patients and, perhaps, leukemic stem cells in some. Treatment efforts have focused on conjugated antibodies, particularly gemtuzumab ozogamicin (GO), an anti-CD33 antibody carrying a toxic calicheamicin-gamma(1) derivative that, after intracellular hydrolytic release, induces DNA strand breaks, apoptosis, and cell death. Serving as paradigm for this strategy, GO was the first anti-cancer immunoconjugate to obtain regulatory approval in the U. S. While efficacious as monotherapy in acute promyelocytic leukemia (APL), GO alone induces remissions in less than 25-35% of non-APL AML patients. However, emerging data from well controlled trials now indicate that GO improves survival for many non-APL AML patients, supporting the conclusion that CD33 is a clinically relevant target for some disease subsets. It is thus unfortunate that GO has become unavailable in many parts of the world, and the drug's usefulness should be reconsidered and selected patients granted access to this immunoconjugate.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available